141 related articles for article (PubMed ID: 22204610)
21. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors.
Niikura N; Liu J; Hayashi N; Mittendorf EA; Gong Y; Palla SL; Tokuda Y; Gonzalez-Angulo AM; Hortobagyi GN; Ueno NT
J Clin Oncol; 2012 Feb; 30(6):593-9. PubMed ID: 22124109
[TBL] [Abstract][Full Text] [Related]
22. Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer.
Park IH; Ro J; Lee KS; Nam BH; Kwon Y; Shin KH
Ann Oncol; 2009 Jan; 20(1):56-62. PubMed ID: 18664558
[TBL] [Abstract][Full Text] [Related]
23. Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT).
Niwińska A; Murawska M; Pogoda K
Ann Oncol; 2010 May; 21(5):942-8. PubMed ID: 19840953
[TBL] [Abstract][Full Text] [Related]
24. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer.
Bartsch R; Rottenfusser A; Wenzel C; Dieckmann K; Pluschnig U; Altorjai G; Rudas M; Mader RM; Poetter R; Zielinski CC; Steger GG
J Neurooncol; 2007 Dec; 85(3):311-7. PubMed ID: 17557136
[TBL] [Abstract][Full Text] [Related]
25. Trastuzumab-based Retreatment after Lapatinib in Heavily Pretreated HER2 Positive Metastatic Breast Cancer: an Anatolian Society of Medical Oncology Study.
Uncu D; Bayoglu IV; Arslan UY; Kucukoner M; Artac M; Koca D; Oguz A; Demirci U; Arpaci E; Dogan M; Kucukzeybek Y; Turker I; Isikdogan A; Guler T; Zengin N
Asian Pac J Cancer Prev; 2015; 16(9):4127-31. PubMed ID: 25987098
[TBL] [Abstract][Full Text] [Related]
26. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review.
Dawood S; Broglio K; Buzdar AU; Hortobagyi GN; Giordano SH
J Clin Oncol; 2010 Jan; 28(1):92-8. PubMed ID: 19933921
[TBL] [Abstract][Full Text] [Related]
27. Application of recursive partitioning analysis and evaluation of the use of whole brain radiation among patients treated with stereotactic radiosurgery for newly diagnosed brain metastases.
Chidel MA; Suh JH; Reddy CA; Chao ST; Lundbeck MF; Barnett GH
Int J Radiat Oncol Biol Phys; 2000 Jul; 47(4):993-9. PubMed ID: 10863070
[TBL] [Abstract][Full Text] [Related]
28. Activity of T-DM1 in Her2-positive breast cancer brain metastases.
Bartsch R; Berghoff AS; Vogl U; Rudas M; Bergen E; Dubsky P; Dieckmann K; Pinker K; Bago-Horvath Z; Galid A; Oehler L; Zielinski CC; Gnant M; Steger GG; Preusser M
Clin Exp Metastasis; 2015 Oct; 32(7):729-37. PubMed ID: 26303828
[TBL] [Abstract][Full Text] [Related]
29. Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death.
Le Scodan R; Jouanneau L; Massard C; Gutierrez M; Kirova Y; Cherel P; Gachet J; Labib A; Mouret-Fourme E
BMC Cancer; 2011 Sep; 11():395. PubMed ID: 21929800
[TBL] [Abstract][Full Text] [Related]
30. Extended survival in women with brain metastases from HER2 overexpressing breast cancer.
Church DN; Modgil R; Guglani S; Bahl A; Hopkins K; Braybrooke JP; Blair P; Price CG
Am J Clin Oncol; 2008 Jun; 31(3):250-4. PubMed ID: 18525303
[TBL] [Abstract][Full Text] [Related]
31. Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases.
Bartsch R; Berghoff A; Pluschnig U; Bago-Horvath Z; Dubsky P; Rottenfusser A; DeVries C; Rudas M; Fitzal F; Dieckmann K; Mader RM; Gnant M; Zielinski CC; Steger GG
Br J Cancer; 2012 Jan; 106(1):25-31. PubMed ID: 22127284
[TBL] [Abstract][Full Text] [Related]
32. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.
Metro G; Foglietta J; Russillo M; Stocchi L; Vidiri A; Giannarelli D; Crinò L; Papaldo P; Mottolese M; Cognetti F; Fabi A; Gori S
Ann Oncol; 2011 Mar; 22(3):625-630. PubMed ID: 20724575
[TBL] [Abstract][Full Text] [Related]
33. Trastuzumab and survival of patients with metastatic breast cancer.
Kast K; Schoffer O; Link T; Forberger A; Petzold A; Niedostatek A; Werner C; Klug SJ; Werner A; Gatzweiler A; Richter B; Baretton G; Wimberger P
Arch Gynecol Obstet; 2017 Aug; 296(2):303-312. PubMed ID: 28616827
[TBL] [Abstract][Full Text] [Related]
34. Incidence of brain metastases in early stage HER2 3+ breast cancer patients; is there a role for brain CT in asymptomatic patients?
Tomasevic ZI; Rakocevic Z; Tomasevic ZM; Milovanovic Z; Inic M; Kolarevic D; Lukic V; Kovac Z
J BUON; 2012; 17(2):249-53. PubMed ID: 22740201
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of trastuzumab in unselected patients with HER2-positive metastatic breast cancer: a retrospective analysis.
Collovà E; Ferzi A; Scandurra G; Aurilio G; Torri V; Porcu L; Sanò MV; Taibi E; Foglietta J; Generali D; Andreis D; Dazzani MC; Bramati A; Marcon I; Atzori F; Cinieri S; Tondulli L; Grasso D; Nolè F; Petrella MC; Gori S; La Verde N
Tumori; 2014; 100(4):426-31. PubMed ID: 25296592
[TBL] [Abstract][Full Text] [Related]
36. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
[TBL] [Abstract][Full Text] [Related]
37. Radiotherapy for brain metastases from renal cell cancer: should whole-brain radiotherapy be added to stereotactic radiosurgery?: analysis of 88 patients.
Fokas E; Henzel M; Hamm K; Surber G; Kleinert G; Engenhart-Cabillic R
Strahlenther Onkol; 2010 Apr; 186(4):210-7. PubMed ID: 20165820
[TBL] [Abstract][Full Text] [Related]
38. The effect of early detection of occult brain metastases in HER2-positive breast cancer patients on survival and cause of death.
Niwińska A; Tacikowska M; Murawska M
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1134-9. PubMed ID: 19932944
[TBL] [Abstract][Full Text] [Related]
39. Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients.
Park YH; Park MJ; Ji SH; Yi SY; Lim DH; Nam DH; Lee JI; Park W; Choi DH; Huh SJ; Ahn JS; Kang WK; Park K; Im YH
Br J Cancer; 2009 Mar; 100(6):894-900. PubMed ID: 19240719
[TBL] [Abstract][Full Text] [Related]
40. Stereotactic radiosurgery alone versus resection plus whole-brain radiotherapy for 1 or 2 brain metastases in recursive partitioning analysis class 1 and 2 patients.
Rades D; Bohlen G; Pluemer A; Veninga T; Hanssens P; Dunst J; Schild SE
Cancer; 2007 Jun; 109(12):2515-21. PubMed ID: 17487853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
